Home Healthcare Medical Devices United Kingdom Autoinjectors Market

United Kingdom Autoinjectors Market Size, Share & Trends Analysis Report By Product Type (Disposable Autoinjectors, Reusable Autoinjectors), By Indication (Rheumatoid Arthritis, Multiple Sclerosis, Diabetes, Anaphylaxis, Other Therapies), By End Use (Homecare Settings, Hospitals & Clinics, Ambulatory Surgical Centers) and Forecasts, 2026-2034

Last Updated: September 01, 2026 | Author: Debashree Bora | Format:

Market Overview

The United Kingdom Autoinjectors Market size was valued at USD 628 million in 2025 and is projected to grow from USD 682.13 million in 2026 to reach USD 1321.75 billion by 2034, growing at a CAGR of 8.62% during the forecast period 2026–2034.

An autoinjector is a medical tool used to administer a certain amount of medication, usually by injection. It is made to be simple to use by the patient or caregiver. It often includes a pre-filled syringe, a needle, and a spring-loaded mechanism that releases the medication fast and easily with the push of a button. Common uses for autoinjectors include treating, among others, illnesses including allergies, arthritic, and multiple sclerosis. They can help lower the danger of unintentional needle stick injuries and are frequently utilized in emergency settings where quick drug administration is required.

Market Key Takeaways

Global Market Size & Growth

Anaphylaxis dominates the market by therapy.
Disposable dominates the market by type.
Home care dominates the market by end-user.
United Kingdom Autoinjectors Market Size

Download a Free Sample To learn more about this report.

Segmental Analysis

The United Kingdom autoinjectors market is segmented based on therapy, type, and end-user.

The market is further segmented by therapy into Anaphylaxis, Rheumatoid Arthritis, Psoriasis, migraines, Cardiovascular-diseases, and others.

The Anaphylaxis segment dominates the market and is expected to grow at a CAGR of 19.4% during the forecast period.

United Kingdom Autoinjectors Market Size By Segments

Request Customizationto receive a tailored report.

The market is further segmented by type into Disposable, Reusable.

Disposable dominated the market and is expected to register a CAGR of 19.2% over the forecast period.

The market is further segmented by end-user into Hospitals and clinics, home care, and others.

The home care segment dominates the market and is expected to grow at a CAGR of 20.4% during the forecast period.

United Kingdom Autoinjectors Market Share By Segments

Speak to an Analystto discuss market opportunities.

Regional Analysis

The U.K. autoinjectors market will expand at the quickest rate due to the rising prevalence of anaphylaxis and the rising number of adrenaline autoinjectors (AAI) prescriptions. According to a study by NCBI, the incidence rate of anaphylaxis in the United Kingdom has risen sharply since 2012. The rate at which AAI is prescribed for each child is likewise increasing. Consequently, the U.K. autoinjectors market is anticipated to expand significantly throughout the predicted timeframe.

Growth in both areas will be sparked by introducing cutting-edge drug delivery methods and devices and attractive reimbursement policies for key companies.

Compared to other European countries, the U.K. has been shown to use diabetes pens extensively. The World Health Organization estimates that 60 million individuals in the European Region have diabetes, with people over 25 having a higher disease prevalence. A low population seeking treatment coupled with social stigma in some areas, poor awareness, and relatively limited access to healthcare facilities, particularly in developing countries, are a few obstacles that restrict the region's potential for growth.

List of Key and Emerging Players in United Kingdom Autoinjectors Market

Pfizer Inc. (Meridian Medical Technologies, Inc.)
AbbVie Inc.
Sanofi
SHL Group
Becton, Dickinson, and Company
Biogen
Mylan N.V.
Novartis AG
Antares Pharma
Ypsomed AG
Haselmeier

Key Industry Developments

June 2026
Ypsomed announced the commercial launch of its next-generation YpsoMate® 5.5 autoinjector for high-volume subcutaneous drug delivery in Europe, including the UK. The device supports biologics and high-viscosity formulations with enhanced usability and sustainability features.
March 2026
SHL Medical received the Zug Innovation Prize 2025 for its Elexy™ autoinjector and continued expanding commercialization of the platform across Europe, including the UK biopharmaceutical market. Elexy is designed for adaptable injection volumes and high-viscosity biologics, supporting next-generation self-injection therapies.
November 2025
Owen Mumford Pharmaceutical Services launched enhancements to its Aidaptus® reusable autoinjector platform, expanding compatibility with multiple syringe formats and supporting sustainable self-administration solutions for pharmaceutical partners developing biologic therapies.
September 2025
Nemera expanded its autoinjector development capabilities by strengthening services for combination products and drug-device development programs across Europe, including support for UK pharmaceutical companies developing injectable biologics.

Report Scope

Segmentation

By Product Type 2
  • Disposable Autoinjectors
  • Reusable Autoinjectors
By Indication 5
  • Rheumatoid Arthritis
  • Multiple Sclerosis
  • Diabetes
  • Anaphylaxis
  • Other Therapies
By End Use 3
  • Homecare Settings
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
Competitive Coverage Pfizer Inc. (Meridian Medical Technologies, Inc.) · AbbVie Inc. · Sanofi · SHL Group · Becton, Dickinson, and Company
Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs)

The United Kingdom autoinjectors market size was valued at USD 628 million in 2025 and is projected to grow from USD 682.13 million in 2026 to reach USD 1321.75 billion by 2034, growing at a CAGR of 8.62% during the forecast period 2026–2034.

Growing incidences of anaphylactic shock are the key driver supporting the growth of the United Kingdom market.

The disposable segment is the leading segment of the market during the forecast period.

The key players in the United Kingdom market include Sanofi, SHL Group, Biogen, Mylan N.V., Novartis AG, Antares Pharma, Ypsomed AG, and Haselmeier.
About the Author
Debashree Bora
Debashree Bora
Healthcare Lead

Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, and competitive dynamics.
Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.

Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Request Sample Order Report Now

We are featured on: